RON Inhibitors
1 drugsAbout RON
RON, also known as Recepteur d'Origine Nantais, is a receptor tyrosine kinase (RTK) involved in cell growth and survival. RTKs are cell surface receptors; their aberrant activation is frequently observed in cancers, making them therapeutic targets.
RON is a compelling oncology target, but currently lacks genetic evidence supporting its role in disease. Its presence on the cell surface makes it accessible to antibody and small molecule therapeutics.
RON is currently targeted by one FDA-approved drug, XALKORI, a small molecule with oncology indications. XALKORI was first approved in 2011, and no other drugs have been approved since.
Top RON Drugs
The competitive landscape is limited, with only one company, PF PRISM CV, having an approved drug.
Low competition suggests an opportunity for new entrants to develop RON-targeting therapies.
RON Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets RON, using small molecule modality.
Explore opportunities for novel modalities like antibodies or PROTACs to target RON.
RON Clinical Trials 85 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on RON. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 33 | 25 | 6 | 2 | 81% |
| Phase 2 | 34 | 14 | 6 | 14 | 70% |
| Phase 3 | 15 | 5 | 0 | 10 | 100% |
| Phase 4 | 3 | 0 | 2 | 1 | 0% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
3 Phase 3 trials testing approved RON drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting RON. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
RON Drug Approval Timeline (2011 - 2011)
The approval timeline shows that XALKORI was approved in 2011 and no new drugs have been approved since.
The lack of recent approvals indicates potential saturation or challenges in developing new RON inhibitors.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 42 (10 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on RON. A trial counts if an approved drug acting on RON is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.